Cardio Ultraefficient nanoParticles for Inhalation of Drug prOducts
The incidence of Cardiovascular Disease (CD) claims worldwide 17.1 million lives a year, with an estimated 31% of all deaths globally and a EU cost of 139 billion euros. Up to 40% of all deaths occur among the elderly. In spite of...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NanoMATe
Nanoparticles for Molecular Imaging of Atherosclerosis from...
183K€
Cerrado
NANOATHERO
Nanomedicine for target specific imaging and treatment of at...
13M€
Cerrado
MAT2016-80266-R
NANOSONDAS HIBRIDAS INTELIGENTES PARA BIOIMAGEN, MONOTORIZAC...
182K€
Cerrado
SAF2014-59118-JIN
NANOQUIMERAS MULTIFUNCIONALES BASADAS EN PROTEINAS COMO NANO...
204K€
Cerrado
MAT2016-75362-C3-2-R
NANOMATERIALES PARA EL DIAGNOSTICO DE LESIONES CARDIOVASCULA...
91K€
Cerrado
DELIVER
Release of engineered extracellular vesicles for delivery of...
2M€
Cerrado
Información proyecto CUPIDO
Duración del proyecto: 50 meses
Fecha Inicio: 2016-11-22
Fecha Fin: 2021-01-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The incidence of Cardiovascular Disease (CD) claims worldwide 17.1 million lives a year, with an estimated 31% of all deaths globally and a EU cost of 139 billion euros. Up to 40% of all deaths occur among the elderly. In spite of all medical efforts, the 5-year mortality was reduced significantly less than that of malignant diseases. This highlights the urgent need to overcome the difficulties associated with present pharmacological therapies (i.e. drug instability, and unspecific targeting) by developing new ground-breaking therapeutic strategies that go far beyond any current regimens. New approaches for safe, efficient, and heart-specific delivery of therapeutics are strongly required. CUPIDO is envisioned to meet these critical needs by providing an unconventional and effective strategy based on nanoparticle-assisted delivery of clinically available and novel therapeutics to the diseased heart. In particular, CUPIDO will develop innovative bioinspired hybrid nanoparticles formulated as biologicals delivery, which are i) biocompatible and biodegradable, ii) designed for crossing biological barriers, and iii) guidable to the heart. A combination of multidisciplinary manufacturing and validation approaches will be employed, bringing the envisioned product beyond the currently available clinical and day-to-day management of CD individuals. Scale-up production, and respect of medical regulatory requirements will allow CUPIDO to deliver a final product for future late pre-clinical and clinical studies. Altogether, CUPIDO will foster the translation of nanomedical applications toward the cardiac field, which although still in its start, offers great potential to overcome the limitations associated to the currently pharmacological treatments.